On Monday, June 15, 2020, the U.S. Food and Drug Administration removed the Emergency Authorization Use (EAU) of two malaria drugs to treat COVID-19, saying that they are “unlikely to be effective.”
Both hydroxychloroquine (brand name Plaquenil) and chloroquine were heavily promoted by President Trump after a handful of small, poorly controlled studies showed that they could work in treating the disease.
The FDA reported that further studies had shown that the two drugs were unlikely to be effective in stopping the virus, and that current national treatment guidelines do not recommend using them outside of clinical trials.
Hydroxychloroquine is a low-risk ototoxic drug. Please refer to this feature article for more information.
Recent Posts
Does my dog hate my music?
Have you ever seen your dog react negatively to music that you’re listening to? It’s probably not a judgment on your musical taste, but rather a…
Medicaid in Focus: What Audiologists Need to Know Now
With the recent changes to Medicaid, the Academy is preparing audiologists with the new one-pager, “Audiology in Medicaid”, an exclusive member resource designed to educate on…
American Academy of Audiology Clinical Consensus Statement: Assessment of Vestibular Function in the Pediatric Population
Authors: Violette Lavender, AuD, Kristen Janky, PhD, Katheryn Bachmann, PhD, Melissa Caine, AuD, Micheal Castiglione, AuD, Guangwei Zhou, ScD The American Academy of Audiology Clinical…